• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population.

作者信息

Khaki Ali Raza, Glisch Chad, Petrillo Laura A

机构信息

Ali Raza Khaki, MD, MS, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA; Chad Glisch, MD, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and Laura A. Petrillo, MD, Division of Palliative Care and Geriatrics, Department of Medicine, Massachusetts General Hospital, Boston, MA.

出版信息

JCO Oncol Pract. 2021 Sep;17(9):583-586. doi: 10.1200/OP.21.00397. Epub 2021 Jul 23.

DOI:10.1200/OP.21.00397
PMID:34297600
Abstract
摘要

相似文献

1
Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population.体能状态较差患者的免疫治疗：针对这一特殊人群尚无定论。
JCO Oncol Pract. 2021 Sep;17(9):583-586. doi: 10.1200/OP.21.00397. Epub 2021 Jul 23.
2
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.体能状态为2的非小细胞肺癌患者的免疫治疗：证据匮乏情况下的临床决策
J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.
3
Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer.免疫治疗在 IV 期非小细胞肺癌中的挑战。
JCO Oncol Pract. 2021 Aug;17(8):465-471. doi: 10.1200/OP.20.00949. Epub 2021 Mar 15.
4
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.免疫治疗的非小细胞肺癌患者的免疫RECIST标准及症状性假性进展
Radiol Oncol. 2018 Oct 18;52(4):365-369. doi: 10.2478/raon-2018-0037.
5
Siglec-15: An Attractive Immunotherapy Target.Siglec-15：一种有吸引力的免疫治疗靶点。
Cancer Discov. 2020 Jan;10(1):7-8. doi: 10.1158/2159-8290.CD-NB2019-136. Epub 2019 Dec 5.
6
Immunotherapy in lung cancer: effective for patients with poor performance status?肺癌免疫疗法：对身体状况较差的患者有效吗？
Lancet Respir Med. 2020 Sep;8(9):838-839. doi: 10.1016/S2213-2600(20)30107-7. Epub 2020 Mar 19.
7
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.非小细胞肺癌的免疫疗法：一种新的治疗算法。
Eur Respir J. 2020 Feb 6;55(2). doi: 10.1183/13993003.01907-2019. Print 2020 Feb.
8
[Insights on immunotherapy in pulmonary oncology].[肺部肿瘤免疫治疗的见解]
Rev Med Suisse. 2018 Aug 22;14(615):1451-1454.
9
Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.非小细胞肺癌免疫治疗的临床方法：现状和未来展望。
Curr Mol Pharmacol. 2016;9(3):183-195. doi: 10.2174/1874467208666150716120108.
10
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.

引用本文的文献

1
The prognostic value of a laboratory cachexia score (LCAS) defined by LDH, CRP and albumin in patients with advanced lung cancer.由乳酸脱氢酶（LDH）、C反应蛋白（CRP）和白蛋白定义的实验室恶病质评分（LCAS）在晚期肺癌患者中的预后价值。
BMC Cancer. 2025 Mar 25;25(1):543. doi: 10.1186/s12885-025-13426-3.
2
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.PD-(L)1 单药阻断疗法与 PD-(L)1 单药阻断联合化疗一线治疗 PD-L1 阳性晚期肺腺癌的疗效：一项队列研究。
J Immunother Cancer. 2023 Jul;11(7). doi: 10.1136/jitc-2023-006994.
3
Associations between treatments, comorbidities and multidimensional aspects of quality of life among patients with advanced cancer in the Netherlands-a 2017-2020 multicentre cross-sectional study.
荷兰晚期癌症患者的治疗、合并症与多维生活质量之间的关联：一项 2017-2020 年多中心横断面研究。
Qual Life Res. 2023 Nov;32(11):3123-3133. doi: 10.1007/s11136-023-03460-8. Epub 2023 Jun 30.
4
Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.免疫治疗的挑战：免疫检查点抑制剂治疗的观点和局限性。
Int J Mol Sci. 2022 Mar 5;23(5):2847. doi: 10.3390/ijms23052847.